At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia
In Brief
A Phase 3 clinical trial evaluating 1mg Finasteride active, 0.02mg dutasteride, and 4 other interventions for Androgenetic Alopecia. Completed, enrolled 917 participants across 39 sites in 9 countries.
Detailed Summary
The purpose of this six month study is to show that dutasteride is safe and more effective than placebo, and at least as safe and effective as finasteride in treating hair loss in men with androgenetic alopecia. Three doses of dutasteride will be investigated.
Study Details
Timeline
Interventions
1mg finasteride active, by mouth once daily
0.02mg dutasteride active, by mouth once daily
0.1mg dutasteride active, by mouth once daily
0.5mg dutasteride active, by mouth once daily
finasteride placebo, by mouth once daily
dutasteride placebo, by mouth once daily